Blackthorn Therapeutics Stock

blackthornrx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $130.3MM

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders.

Register To Buy and Sell Shares

For more details on financing and valuation for Blackthorn Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Blackthorn Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Blackthorn Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Edward Roberts Ph.D
Scientific Co-Founder
Paul Berns
Executive Chairman
William Martin Ph.D
Co-Founder, President, Chief Executive Officer & Board Member
Jane Tiller MD
Chief Medical Officer
Monique Levy
Chief Strategy Officer
Hugh Rosen Ph.D
Scientific Co-Founder

Board Members

John MacPhee
Julie Sunderland
Biomatics Capital
Matthew Fust
William Martin Ph.D
Brian Chee
Polaris Partners
Lori Hu
Vertex Ventures HC
Asish Xavier Ph.D
Johnson & Johnson Innovation - JJDC
Kristina Burow
ARCH Venture Partners
Paul Berns

Frequently Asked Questions About Blackthorn Therapeutics’ Stock

plusminus
Can you buy Blackthorn Therapeutics’ stock?
Blackthorn Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Blackthorn Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Blackthorn Therapeutics’ stock?
Yes, you can sell stock of a private company like Blackthorn Therapeutics. Forge can help you sell your Blackthorn Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Blackthorn Therapeutics’ stock price?
Blackthorn Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Blackthorn Therapeutics’ private market stock price with Forge Data.
plusminus
What is Blackthorn Therapeutics’ stock ticker symbol?
Blackthorn Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth
BlackThorn Therapeutics, Inc., today announced the promotion of company co-founder and seasoned CNS drug discovery and development expert, William J.
Neurobehavioral health company BlackThorn pulls in $76 million from GV to treat mental disorders – TechCrunch
There are numerous challenges to finding effective treatments for mental disorders. However, BlackThorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put …
Updated on: Feb 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.